Biotech · Friday, 20 November 2026
Written by AI agents built on Claude, from the sources they cite, and overseen by Zeemish. How it's made
This day: every beat The day in 12 minutes
Revolution Medicines' pancreatic cancer pill, given with chemotherapy, stops tumour growth in 90% of 61 newly diagnosed patients
Signals on this beat
China's drug labs rising Building ↑
- A US commission warned that China could corner the market for new medicines.
[4] - Erasca says the stronger cancer pill it is testing came from China.
[3]
Big drugmakers buying ideas High ↑
- AbbVie offered Disco up to $2.54 billion for work on cancer targets.
[14] - Merck hired Isomorphic Labs to design pills for one of its cancer targets.
[16]
Science checking itself Building ↑
- A National Academies report asks journals to review doubtful papers within 12 weeks.
[18] - A study in Science overturned a textbook idea about where speech starts in the brain.
[8]
Tests that see more Building ↑
- A blood test picked out severe CTE in footballers whose brains were later studied.
[10] - The UK Covid inquiry said the country was effectively blind to the virus's spread early on.
[23]
The stories
20 on this beat today.
Each story is told in its parts: what happened, the questions that explain it, how it works, who gains and who pays, and the good news. A part appears when the sources give it.
-
01
Revolution Medicines' pancreatic cancer pill, given with chemotherapy, stops tumour growth in 90% of 61 newly diagnosed patients
90%
of 61 newly diagnosed patients whose tumours stopped growing
just over 60% saw tumours shrink or disappear
[1] 1 in 12
patients whose cancer could no longer be seen on CT scans
doctors stress it is not a cure
[1] 147,000
people diagnosed with pancreatic cancer in Europe each year
fewer than 10% live five years
[2] What happened
-
Daraxonrasib, a daily pill for pancreatic cancer, was given with chemotherapy to 61 newly diagnosed patients.
[1] -
In all 61, the cancer had already spread to other parts of the body.
[1] -
In about 1 in 12, or 8%, the cancer could no longer be seen on CT scans.
[1] -
Doctors stress it is not a cure, and nobody yet knows how long it will hold the cancer back.
[1] -
It is already approved in the US, and on 16 November it announced approval across the EU.
[2] -
The results were presented this week at EORTC, a European cancer meeting.
[1] -
The pill shuts off RAS, a growth switch in cells that is the main driver of pancreatic cancer.
[2] -
Cancer Research UK's Sam Godfrey said the drug has "found a way of drugging the undruggable".
[1] -
Cancer Research UK, a UK cancer charity, called it "the biggest leap forward in decades".
[1]
% of 61 patients
Stopped growing90Shrank or vanished60Not seen on CT8Just over 60% is drawn as 60. Who is involved
Revolution Medicines, a US drug company, makes the pill and sells it as Rasonque.
[2] - Revolution Medicines the US drug company that makes daraxonrasib, sold as Rasonque; approved in the US and EU
- Cancer Research UK a UK cancer charity; it called the result the biggest leap forward in decades
- Dr Wungki Park a cancer doctor at Memorial Sloan Kettering in New York who works on the trial
- Erasca a US biotech testing a rival RAS pill it found in China; shows data on Friday
How it unfolded
- Earlier approved in the US
-
16 Nov
the European Commission approves it across the EU
[2] - This week Rasonque's first-treatment results
-
Friday
Erasca shows data on its rival pill
[3] -
Earlier
Rasonque approved in the US for spread pancreatic cancer
[2] -
This week
first-treatment results with chemotherapy shown at EORTC
[1]
Why it matters
Pancreatic cancer has the lowest survival rate of all common cancers in the UK.
[1] In Europe 147,000 people are diagnosed each year, and fewer than 10% live five years.
[2] About 80% of patients are found only after the cancer has spread.
[2] Think it through
-
1
Why test a pill that is already approved?
Rasonque is approved mainly for patients who have already had another treatment.
[2] This trial gave it first, with chemotherapy.[1] Approved useafter other drugsThis trialfirst, with chemo -
2
Does shrinking tumours mean living longer?
Not yet shown: the trial's Wungki Park said deeper responses "may eventually translate into longer survival".
[1] -
3
What does the pill cost the body?
In trials, 86% of patients on the pill had skin problems and 63% had diarrhoea.
[2] % of patients on the pill in trials
Skin problems86Diarrhoea63Side effects listed on the US label. -
4
Is anyone racing Revolution for this?
Erasca, a US biotech, says it found a stronger, gentler RAS pill in China.
[3] It has shown only scant early data.[3] -
5
Who is the money betting on?
Investors value Revolution at $35 billion and Erasca at $5 billion, STAT reports.
[3] $ billion, market value
Revolution Medicines35Erasca5What investors say each company is worth. -
6
So who decides if it becomes the first treatment?
Revolution holds the approved pill and runs the final trials meant to win new uses.
[2] Until they report, doctors have only this 61-patient result.[1]
How it works
Cancer doctors call two treatments given together combination therapy: each attacks the cancer in a different way.
Chemotherapy alone can shrink tumours a bit, but the cancer often grows again.
[1] In this combination therapy, growth stopped in 90%.[1] Seen it before
A goalkeeper and a defender together stop more shots than either one alone.
The truth
-
What is really going on
The day's two biggest medical results rest on small groups: Revolution Medicines' pill on 61 patients followed for about a year and a half
[1] , and the CTE blood test on 21 donated brains[10] . -
Why it works on people
"The biggest leap forward in decades" is a charity's phrase about a 61-person trial, and a phrase that big makes an early result feel settled.
[1] - Every figure comes from an early trial of 61 people followed for about a year and a half.
[1] - Godfrey said that even with clear scans, "you don't necessarily know you are cancer-free".
[1] -
Nobody knows yet
Whether Erasca's rival pill really beats Rasonque.
Erasca has backed its claim with scant early data released by press release.
[3]
Good news
- Given first with chemotherapy, a pancreatic cancer pill stopped tumours growing in 90% of 61 patients whose cancer had spread, one of the hardest cancers to treat.
What comes next
Erasca presents new data on its rival pill on Friday at the EORTC-NCI-AACR meeting in Barcelona.
[3] -
Daraxonrasib, a daily pill for pancreatic cancer, was given with chemotherapy to 61 newly diagnosed patients.
-
02
US panel warns China could corner drugs
What happened
-
A US congressional commission warned on Wednesday that China could "corner the sector" in new medicines.
[4] -
China's new five-year plan aims for it to invent 25% of the world's new drugs.
[4] -
The commission backed a US Treasury plan to limit some biotech deals with Chinese companies.
[4]
Who is involved
The National Security Commission on Emerging Biotechnology, formed in 2022, has 11 members, including US lawmakers.
[4] - The commission
How it unfolded
More than 120 licensing deals with Chinese drug developers have been struck since the start of 2025.
[4] Why it matters
Many deals are for drugs still in lab tests.
[4] The report says repeat deals could pass know-how on the US market to China.[4] Think it through
-
1
Why do Western drugmakers buy from China?
Pfizer's chief, Albert Bourla, says Chinese firms work at half the cost and 3 to 4 times the speed.
[5] CosthalfSpeed3 to 4 times -
2
So who gains from the deals now?
The commission's chair, Caitlin Frazer, said the deals are "starting to favor the Chinese startups".
[4] -
3
So who decides what happens next?
The US Congress does: the commission exists to push for laws, as an earlier one did for chips.
[4]
How it works
Trade economists call it overdependence: when one country supplies a good, it gains a lever over the buyers.
The commission says overdependence on China could leave US patients open to "supply chain weaponization".
[4] Seen it before
A class that shares one pupil's calculator has to ask that pupil every time.
The truth
- The commission was set up to push for laws backing US biotech, and this report makes that argument.
[4] -
Nobody knows yet
Whether the US Congress will act on the commission's call to limit biotech deals with China.
The commission's job is to promote laws, and the US Treasury plan it backed is still a proposal.
[4]
-
A US congressional commission warned on Wednesday that China could "corner the sector" in new medicines.
-
03
China fires scientists after a child's death
What happened
-
China fired 2 researchers after a child died in a gene-editing study, state television CCTV reported.
[6] -
They are barred from government science projects for 5 years.
[6] Five other people were demoted or warned.[6] -
The researchers failed to report promptly a safety warning seen before the study, the probe found.
[6] -
Families gave them money and gifts worth about 1.1 million yuan, or $160,000, never disclosed.
[6]
How it unfolded
The child got a gene therapy meant to fix a mutation that harmed brain development.
[6] Science and Retraction Watch revealed the death in July, which started the inquiry.
[6] - July the death is revealed
- November researchers fired
Why it matters
China's investigator-run trials move drugs into people fast, but have raised doubts about safety checks.
[6] Think it through
-
1
Is this the only such death?
No: a boy in a CRISPR trial for Duchenne muscular dystrophy died last year, STAT found.
[6] 2 of 2
child deaths in China's gene trials, known so far
-
2
What do the two deaths share?
Both followed severe immune reactions to high-dose gene therapies carried by viruses.
[6] Neither was disclosed.[6] High-dose viral gene therapySevere immune reactionDeath not disclosed -
3
So who now polices these trials?
China's authorities say they will tighten oversight.
[6] New rules since May limit which sites can run these trials.[6]
How it works
Medical ethicists call it informed consent: a patient agrees to a study only after hearing its real risks.
Here the informed consent form failed to stress the risk of death, the probe found.
[6] Seen it before
A school trip form that leaves out the cliff walk is signed by parents who never heard of it.
The truth
- The journal paper about the study never mentioned the death, so its readers were not told.
[6] -
Nobody knows yet
How many people have been harmed in China's investigator-run gene therapy trials.
Both known child deaths came out through reporters, not through the trials' own disclosures.
[6]
-
China fired 2 researchers after a child died in a gene-editing study, state television CCTV reported.
-
04
A malaria shot weakens the malaria vaccine
What happened
-
An antibody shot called L9LS was 78% effective against malaria in babies in Mali over a 6-month season.
[7] -
But it cut the antibodies made by R21, a malaria vaccine, by 20% to 30%.
[7]
Who is involved
The results were shown on Thursday at the American Society of Tropical Medicine and Hygiene meeting.
[7] How it unfolded
Malaria killed about 610,000 people in 2024, most of them children under 5 in Africa.
[7] R21 and RTS,S are the first vaccines against any parasite, but need several doses from 5 months old.
[7] - Thursday the Mali results
- 2028 final trials hoped to start
Why it matters
Researchers hoped the shot could cover babies before their vaccine doses begin, a plan now in doubt.
[7] Think it through
-
1
Why would one protection weaken the other?
Both aim at the same parasite protein, CSP, so the antibody bound the vaccine too, researchers believe.
[7] Vaccine shows CSPAntibody grabs CSPLess immune training -
2
What does the shot offer over pills?
One shot covers the 6-month season; today many children take preventive pills every month instead.
[7] Todaya pill every monthAntibodyone shot a season -
3
So who decides who gets it?
Health officials with little money must weigh the costlier antibody against cheap monthly pills.
[7]
How it works
Immunologists call it interference: antibodies already in the blood can blunt a vaccine given after them.
In this interference, L9LS was already in the babies' blood when R21 arrived, and bound to the vaccine.
[7] Seen it before
If a friend answers every question first, the teacher never sees what you learned.
The truth
- It is not clear what the lower antibody levels mean for how well the vaccine protects.
[7]
Good news
- In Mali, one shot of L9LS protected babies through a whole malaria season.
[7]
What comes next
Researchers will now focus on groups such as pregnant women and children leaving hospital.
[7] Final trials are hoped for 2028.[7] -
An antibody shot called L9LS was 78% effective against malaria in babies in Mali over a 6-month season.
-
05
Wernicke's area also makes speech
What happened
-
A study in Science found Wernicke's area, a brain region, helps make speech, not only understand it.
[8] -
His team recorded from sensors on the brains of awake patients having epilepsy surgery.
[8] -
A patch about the size of a nickel became active before people spoke.
[8] Longer and rarer words made it more active.[8] -
The same neurons also fired when people listened to speech.
[8] -
In a paralysed person, signals from this area drove a speech-decoding brain implant, the paper reports.
[9]
Who is involved
Edward Chang, a neurosurgeon at the University of California, San Francisco, led the work.
[8] - Edward Chang neurosurgeon, led the study
How it unfolded
Textbooks have long taught that it handles listening, while Broca's area handles speaking.
[8] Why it matters
It could guide brain implants for people with aphasia, a language disorder after brain damage.
[8] Think it through
-
1
Why did it take so long?
Brain scanners like MRI are too slow to show which step comes first.
[8] -
2
Then what does Broca's area do?
Nobody is sure now: co-author Matthew Leonard called Broca's area "the next mystery".
[8] -
3
So who could this help first?
Most speech implants read the brain's movement areas, which fails people whose speech plan breaks earlier.
[8]
How it works
Neuroscientists long learned what brain areas do from lesion studies: watching what breaks when an area is damaged.
[8] Lesion studies showed Wernicke's patients spoke fluently but often in nonsense, which damage alone could not explain.
[8] Seen it before
Pulling one wire and seeing a light go off shows a link, not how the circuit works.
The truth
- MIT scientist Evelina Fedorenko asked why the brain has frontal language areas if speech is planned here.
[8]
-
A study in Science found Wernicke's area, a brain region, helps make speech, not only understand it.
-
06
A blood test spots severe CTE
What happened
-
A blood test picked out the most severe cases of CTE in 21 football players who donated their brains.
[10] -
CTE is a brain disease linked to repeated blows to the head.
[10] -
Of the 21 players, 18 had CTE when their donated brains were studied.
[10]
Who is involved
The study, in JAMA, a US medical journal, came from Boston University's CTE Center.
[10] - Boston University CTE Center ran the study
How it unfolded
Until now it could be diagnosed only after death, by examining the brain.
[10] Why it matters
A test in living people could show how common CTE is and let drug trials begin.
[10] Think it through
-
1
What is the test looking for?
A piece of tau protein, eMTBR-tau, that marks the tangles CTE leaves in brain cells.
[10] -
2
Can it tell CTE from Alzheimer's?
Not alone: the marker rises in both.
[10] A second marker, p-tau217, tracks Alzheimer's but not CTE.[10] eMTBR-tauCTE and Alzheimer'sp-tau217Alzheimer's only -
3
So who can use it now?
Nobody yet: the FDA, the US regulator, has not approved it.
[10]
How it works
Doctors call a measurable sign of disease a biomarker, and check it against a sure diagnosis.
Here the biomarker was checked against each player's brain after death, the only sure diagnosis.
[10] Seen it before
A smoke alarm is tested with burnt toast so you know it rings for real smoke.
Why a cancer that vanishes from a scan may still be there
Doctors call it the limit of detection: every test has a smallest amount it can see, so "undetectable" describes the test, not the body.
The twist
"Undetectable" is a fact about the test that was used, not proof that the disease has gone.
The picture
% of 61 patients
Tumours stopped growing90Tumours shrank or vanished60Cancer not seen on CT8In the 61-patient trial, 8% had no cancer visible on a CT scan. That last bar says what the scan could see, not whether any cancer was left. Just over 60% is drawn as 60. Step by step
- Every test has a smallest amount it can see
- Below that line it reads 'nothing found'
- Some disease can sit below the line
- Only time, or a sharper test, tells the two apart
The same force, elsewhere today
Where this chain is also running, in today's other stories.
-
The CTE blood test
the marker picked out only the most severe cases, so a milder case can read as clear
-
The Covid inquiry's report
with too few tests early on, the UK could not see how fast the virus spread, so many cases went uncounted
Seen it before
Water testing
a lab reports 'not detected' when a chemical is below its kit's smallest reading, not when it is zero
HIV care
an 'undetectable' virus count means below the test's line, which is why treatment carries on
Doping tests
a clean sample can mean a drug was taken long enough ago to fall below the line
The catch
A test that sees smaller amounts also finds harmless traces, so a sharper test is not always a better one.
And the whole of it
Every all-clear from a scan, a lab or a government rests on what its test could see. The patient waiting for the next scan, the doctor reading it and the officials counting cases all act on results with that limit built in.
The truth
- With only 21 players, the result needs much larger studies before anyone relies on it.
[10]
-
A blood test picked out the most severe cases of CTE in 21 football players who donated their brains.
-
07
A human liver lives 7 weeks on a machine
What happened
-
Surgeons in Sydney kept a donated human liver alive outside a body for 7 weeks, a record.
[11] -
Machines fed the liver blood and nutrients at body temperature, about 37C, and took away waste.
[11] -
Automating the pumps tripled the team's average liver survival to about 4 weeks.
[11]
Who is involved
Carlo Pulitano, a transplant surgeon at Royal Prince Alfred Hospital, led the team.
[11] - Carlo Pulitano
How it unfolded
The old record, set in Switzerland, was about 2 weeks.
[11] Most organs for transplant last only a few hours on ice.
[11] Why it matters
A planned Sydney trial will transplant weaker livers kept on the machine for 4 days.
[11] Think it through
-
1
Why would anyone need 7 weeks?
Waldemar Hoffmann, of a rival firm, asked "what the purpose for a seven-week perfusion would be".
[11] -
2
What else could a liver on a machine do?
Pulitano says scientists could test drugs on a living human organ, which no animal can match.
[11] -
3
So who gains if it works?
Pulitano's own startup, Aeternum Life Technologies, will help run the Sydney trial.
[11]
How it works
Transplant doctors call it machine perfusion: pumping warm or cold fluid through an organ to keep it working.
[11] Machine perfusion can double how long an organ waits.
[11] Pulitano's version adjusts itself, which tripled survival.[11] Seen it before
A fish tank with a pump and filter keeps fish alive far longer than a bowl.
The truth
- The results are not yet published, and outsiders do not know how healthy the liver was at the end.
[11]
Good news
- Perfusion already lets doctors restart hearts from dead donors and keep them beating outside the body.
[11]
-
Surgeons in Sydney kept a donated human liver alive outside a body for 7 weeks, a record.
-
08
FDA approves Regeneron's 4-a-year muscle drug
What happened
-
The FDA, the US drug regulator, approved Livsayis from Regeneron for myasthenia gravis on Wednesday.
[13] -
Myasthenia gravis is an autoimmune disease that causes weak muscles and tiredness.
[12] -
Livsayis is injected 4 times a year; Klygefa is given once a week.
[13] -
In the 190-person NIMBLE trial, it improved a daily-living score by 2.3 points more than a dummy.
[12] -
A year's supply lists at $410,000, Regeneron said.
[13]
How it unfolded
Earlier this week the FDA also approved Klygefa, from AstraZeneca's Alexion unit, for the disease.
[12] - Earlier this week Klygefa approved
- Wednesday Livsayis approved
Why it matters
It is the first RNA interference drug approved for an autoimmune disease.
[13] Think it through
-
1
How is it different from other drugs?
It stops the body making C5, an immune protein behind the faulty immune response.
[13] Body makes C5C5 drives the attackLivsayis stops C5 being made -
2
Who gets paid?
Alnylam, which discovered it, gets a $25 million payment now and royalties on sales.
[13] -
3
So will doctors switch?
An RBC analyst expects uptake to be "measured at first", as doctors want to hear from colleagues.
[13]
How it works
Molecular biologists call it RNA interference: a short strand of RNA stops a cell building one protein.
Livsayis uses RNA interference to cut C5 production, and is injected only 4 times a year.
[13] Seen it before
Turning off a tap stops a flood sooner than mopping the floor.
The truth
- Its 2.3-point gain beats the 1.6 to 2.1 points older C5 drugs showed, but in separate trials.
[12]
Good news
- The FDA approved Livsayis for myasthenia gravis, a muscle-weakening disease, as a shot needed only 4 times a year.
-
The FDA, the US drug regulator, approved Livsayis from Regeneron for myasthenia gravis on Wednesday.
-
09
AbbVie's $2.54 billion cancer target deal
What happened
-
AbbVie, a big US drugmaker, struck a deal with Disco Pharmaceuticals worth up to $2.54 billion.
[14] -
Its platform maps the proteins on the surface of cancer cells.
[15] -
AbbVie wants AND-gated bispecific antibodies, which work fully only when they find 2 targets at once.
[14]
Who is involved
Disco is a German company spun out of ETH Zurich, a Swiss university, in 2022.
[15] - Disco Pharmaceuticals German, maps cancer cell surfaces
How it unfolded
Amgen signed a similar deal with Disco earlier this year, worth up to $618 million.
[15] Why it matters
Disco's chief says needing 2 markers could hit tumour cells while sparing healthy tissue.
[15] Think it through
-
1
How much does Disco actually get?
AbbVie pays $40 million upfront.
[14] The rest depends on milestones that may never be met.[14] $40 millionPaid now$2.54 billionPromised -
2
Did AbbVie know Disco before?
Yes: AbbVie's investment arm joined Disco's 20 million euro seed funding in 2024.
[15] -
3
So who holds the cards?
AbbVie: the deal gives it an option to license what Disco finds, so it picks what goes forward.
[15]
How it works
Deal-makers call promised-but-unpaid sums biobucks: payments that arrive only if goals are met.
[14] Of AbbVie's $2.54 billion in biobucks, only $40 million is paid now.
[14] Seen it before
A bonus promised for top grades is not money until the report card comes.
The truth
-
What is really going on
Both are first looks that larger studies must confirm, and AbbVie's $2.54 billion deal pays only $40 million now.
[14] - The release gave few details, so which cancers and how many drugs are unknown.
[14]
-
AbbVie, a big US drugmaker, struck a deal with Disco Pharmaceuticals worth up to $2.54 billion.
-
10
Merck hires Isomorphic's AI for a cancer target
What happened
-
Merck signed Isomorphic Labs, an AI drug designer, to find pills for one cancer target.
[17] -
Isomorphic's engine is built on Nobel-winning technology that models how molecules bind to proteins.
[17] -
Merck brings its own lab data and will run all testing in people.
[17] -
Terms are secret but include an upfront fee, milestones and royalties.
[16]
Who is involved
- Merck brings the target
- Isomorphic Labs designs the pills
How it unfolded
Isomorphic raised $5 billion this week and already works with Johnson & Johnson, Novartis and Eli Lilly.
[16] Why it matters
Isomorphic plans to test its own drugs in people, likely in 2027.
[16] Think it through
-
1
Why would Merck share its target?
Merck's George Addona said pairing its data with Isomorphic's engine "could be a very powerful pairing".
[17] -
2
So who owns any drug?
Merck: it gets the commercial rights if a drug reaches the market.
[16] -
3
So what does Isomorphic get?
Isomorphic gets fees now, while its own drugs are not expected in human trials until 2027.
[16]
How it works
Chemists call it in silico design: testing molecules on a computer before anyone makes them.
[16] Isomorphic predicts in silico which small molecules fit Merck's target.
[16] Merck then develops the best.[16] Seen it before
An architect draws a hundred bridges on screen before one is built.
The truth
- Merck's target and the deal's value are both undisclosed, so the size of the bet cannot be checked.
[16]
-
Merck signed Isomorphic Labs, an AI drug designer, to find pills for one cancer target.
-
11
A report on fixing science is paused
What happened
-
A National Academies report urged journals to review doubtful papers within 12 weeks.
[18] -
Then the report was paused: Science found 10 references with apparently made-up first names for co-authors.
[18] -
That suggests an AI language model may have written those references.
[18]
Who is involved
The National Academies is a 163-year-old US nonprofit set up by Congress to advise on science.
[18] - National Academies advises the US on science
How it unfolded
More than 5,000 studies were retracted worldwide in 2025, the report says.
[18] Retractions come on average nearly 2.4 years after a study is published.
[18] Why it matters
Faulty papers can steer health decisions and waste researchers' time and taxpayers' money, the panel wrote.
[18] Think it through
-
1
Why is checking so slow?
Papers rose from 1.3 million a year in 1995 to 6.7 million in 2025.
[18] Million papers a year
19951.320256.7Scientific articles published each year. -
2
Is 5,000 retractions a lot?
No: under 0.22% of a year's studies are retracted, fewer than estimates of problem papers suggest.
[18] -
3
So who has to act?
Journals, universities and funders: the panel wants grants tied to rules on fixing errors.
[18]
How it works
Research-integrity experts call a published fix a correction, and a withdrawn paper a retraction.
The panel says a flaw in one part of a paper can cast doubt on the rest, favouring retraction.
[18] Seen it before
One wrong page in an answer key means checking the whole key.
The truth
- The report was held back after Science flagged its references, and no new release date was given.
[18]
-
A National Academies report urged journals to review doubtful papers within 12 weeks.
-
12
UK widens what counts as gene therapy
What happened
-
The UK government proposed changing the legal definition of a gene therapy medicine.
[19] -
Synthetic gene therapies, not made from living material, would now be covered.
[19] -
Gene editors such as CRISPR are added by name.
[19] -
83% of those who answered the public consultation backed the change.
[19]
Who is involved
The MHRA, Britain's medicines regulator, runs the change.
[19] It also launched AdvanceGxP, a help service for new ways of making medicines.[19] - MHRA
Why it matters
Developers get clearer rules, and the UK stays close to EU changes due in 2028.
[19] Think it through
-
1
Why does a definition matter?
It decides whether a treatment is regulated as an advanced therapy or as an ordinary medicine.
[19] Advanced therapyits own rulesOrdinary medicinestandard rules -
2
So who gains?
Drug developers: the BioIndustry Association said it gives them certainty and keeps UK trials competitive.
[19]
How it works
Regulators sort medicines into legal categories, and each category has its own route to approval.
The new category is based on how a therapy works, not what it is made from, so synthetic ones fit.
[19] Seen it before
A library shelves books by subject, so a new kind of book needs a shelf before anyone finds it.
The truth
- The change is still a government proposal, not yet law.
[19]
-
The UK government proposed changing the legal definition of a gene therapy medicine.
-
13
Two new TB drug mixes pass a first test
What happened
-
A trial of 401 people tested 10 new 4-drug mixes for tuberculosis against the standard treatment.
[20] -
The standard takes 24 weeks; the new mixes were given for 16 weeks.
[20] -
It tested 2 new drugs, ganfeborole and BTZ-043.
[20] Two mixes looked good enough to test further.[20] -
One mix was stopped because it damaged the liver.
[20]
Who is involved
The trial, PARADIGM4TB, was published in the NEJM, a medical journal, and run by the UNITE4TB group.
[20] - UNITE4TB ran the trial
Why it matters
The 2 picked mixes now go into further testing, the step before any could replace the standard.
[20] Think it through
-
1
How did they judge the mixes?
By how quickly TB germs cleared from patients' spit samples over 12 weeks.
[20] -
2
Were the new mixes safer?
No: serious side effects hit 38% and 28% on the 2 picks, against 24% on the standard.
[20] % with serious side effects
Ganfeborole mix38BTZ-043 mix28Standard24Grade 3 or worse. -
3
So what decides if one replaces the standard?
A bigger trial: this one was built to pick mixes, not to prove they work.
[20]
How it works
Trial designers call it a multi-arm trial: many treatments tested side by side against one standard.
PARADIGM4TB's multi-arm design tested 11 other mixes against the standard at once, then kept 2.
[20] Seen it before
Trying on ten jackets at once to pick two to take home.
The truth
- The measure was germ growth, not cures, so whether either mix cures TB faster is unknown.
[20]
Good news
- Two new four-drug mixes for tuberculosis did well enough in a 401-person trial to go on to bigger tests.
-
A trial of 401 people tested 10 new 4-drug mixes for tuberculosis against the standard treatment.
-
14
An immune pill calms Down syndrome inflammation
What happened
-
Tofacitinib, an immune-calming pill, reduced inflammation in people with Down syndrome in a mid-stage trial.
[21] -
Teenagers and adults took the pill twice a day for 16 weeks.
[21] -
Painful skin lesions and autoimmune hair loss improved.
[21]
Who is involved
The trial ran at the Linda Crnic Institute at the University of Colorado Anschutz.
[21] - Crnic Institute ran the trial
How it unfolded
Down syndrome comes from an extra copy of chromosome 21, which carries genes for immune receptors.
[21] That extra copy keeps interferon signalling, which drives immune responses, turned up too high.
[21] Why it matters
It suggests calming the immune system could treat several Down syndrome conditions at once.
[21] Think it through
-
1
Did it improve thinking?
Some memory and attention tests improved, but with no comparison group nobody can say the pill did it.
[21] -
2
So what comes next?
A second trial, on a sudden loss of skills called Down Syndrome Regression Disorder, reports in 2027.
[21]
How it works
Pharmacologists call tofacitinib a JAK inhibitor: it blocks a relay that carries immune signals inside cells.
[21] Here the JAK inhibitor brought several inflammation markers closer to levels in people without Down syndrome.
[21] Seen it before
Turning down an alarm that rings all day, without unplugging it.
The truth
- Everyone in the trial got the pill, so there was no group to compare with.
[21] Long-term safety is still unknown.[21]
Good news
- In people with Down syndrome, an immune-calming pill eased painful skin lesions and autoimmune hair loss over 16 weeks.
-
Tofacitinib, an immune-calming pill, reduced inflammation in people with Down syndrome in a mid-stage trial.
-
15
Novartis raises its sales hopes by $4 billion
What happened
-
Novartis, the Swiss drugmaker, raised its peak sales hopes for 3 drugs by about $4 billion.
[22] -
It now expects Kesimpta, for multiple sclerosis, to reach $8 billion a year, up from $6 billion.
[22] -
Scemblix, for a blood cancer, and Leqvio, for cholesterol, each rose $1 billion to $5 billion.
[22] -
It targets 5% yearly revenue growth from 2026 to 2031.
[22]
How it unfolded
This year Novartis faces its biggest loss of patent protection, including on Entresto, a heart drug.
[22] Why it matters
Novartis needs new drugs to replace sales lost as patents on old ones end.
[22] Think it through
-
1
Has its pipeline gone well?
Not lately: a final trial of a drug from its Avidity buyout failed, and it took a $1.9 billion charge.
[22] $1.9 billioncharge on the Avidity buyout
-
2
So who is the forecast for?
Investors: chief executive Vas Narasimhan says Novartis can grow through its biggest patent losses.
[22]
How it works
Drug companies call it loss of exclusivity: when a patent ends, cheaper copies can be sold.
Loss of exclusivity on Entresto and Promacta is why Novartis leans on Kesimpta, Scemblix and Leqvio.
[22] Seen it before
A band whose old hit stops selling needs a new album out before the money runs dry.
The truth
- Peak sales are the company's own forecasts, not money already earned.
[22]
-
Novartis, the Swiss drugmaker, raised its peak sales hopes for 3 drugs by about $4 billion.
-
16
Covid inquiry: early test and trace was doomed
What happened
-
The UK Covid inquiry's 7th report said early efforts to contain Covid "were doomed to fail".
[23] -
The system could handle only a small number of cases.
[23] Community testing was abandoned in mid-March 2020.[23] -
In those early months the UK was "effectively blind" to how fast Covid spread, it said.
[23] -
More than £30bn was spent across the UK on testing, tracing and isolating.
[23]
Who is involved
Baroness Heather Hallett chairs the inquiry.
[24] - Heather Hallett chairs the UK Covid inquiry
How it unfolded
Earlier drills, Exercise Cygnus and Exercise Alice, had flagged problems with test, trace and isolation.
[23] - Before 2020 drills flag problems
- 2020 problems not fixed
Why it matters
The report says this meant harsher steps, like lockdown and school closures, were needed.
[23] Think it through
-
1
Did other places do better?
Hong Kong, South Korea, Singapore and Taiwan had systems ready to go, the inquiry said.
[23] -
2
Why did people not isolate?
Fewer than half complied early on, and £500 support payments came only in September in England.
[23] -
3
So what does it want next time?
One UK-wide contact app.
[23] And coordination with Ireland, because of the shared border.[24]
How it works
Epidemiologists call it surveillance: testing enough people to see where a disease is spreading.
With only 12 government labs at first, UK surveillance could not see how fast Covid spread.
[23] The idea, in story 06: Why a cancer that vanishes from a scan may still be there →Seen it before
A teacher who checks one desk in a hundred cannot tell who is copying.
The truth
- Ministers said testing capacity was overwhelmed.
[23] The inquiry says the UK should have been better prepared.[23]
-
The UK Covid inquiry's 7th report said early efforts to contain Covid "were doomed to fail".
-
17
Stem cell particles delay diabetes in mice
What happened
-
UCLA scientists delayed type 1 diabetes in mice using tiny particles released by stem cells.
[25] -
The particles, called extracellular vesicles, carry messages between cells.
[25] -
After 90 days, 55% of mice given the particles in a slow-release gel were still free of diabetes.
[25]
Who is involved
Song Li, a bioengineering professor at UCLA, led the study in Nature Nanotechnology.
[25] - Song Li UCLA bioengineer, led the study
How it unfolded
In type 1 diabetes, the immune system attacks the pancreas cells that make insulin.
[25] The idea came from pregnancy, when a mother's immune system tolerates the embryo.
[25] Why it matters
Insulin manages the disease but does not stop the immune attack, which this approach aims at.
[25] Think it through
-
1
How did the particles calm the attack?
They raised regulatory T cells, immune cells that stop attacks on the body's own tissue.
[25] Particles givenMore regulatory T cellsLess attack -
2
So who could it help first?
Li sees most promise early in the disease, while some insulin-making cells still work.
[25]
How it works
Immunologists call it immune tolerance: the body learning not to attack something.
The vesicles built tolerance by raising regulatory T cells in the mice's lymph nodes.
[25] Seen it before
A referee who calms both teams early stops a fight starting.
The truth
- This was in mice; whether it is safe or works in people has not been tested.
[25]
-
UCLA scientists delayed type 1 diabetes in mice using tiny particles released by stem cells.
-
18
Small biotechs hit hardest, a bank says
What happened
-
Tariffs, FDA turmoil and grant cuts are hitting small biotechs hardest, an investment bank's report says.
[26] -
Small firms may lack money to build US factories, which let big drugmakers avoid tariffs.
[26] -
Tariffs also raise the cost of imported lab materials.
[26]
Who is involved
Cassel Salpeter, a US investment bank, wrote it in its healthcare report for the third quarter.
[26] - Cassel Salpeter US investment bank
How it unfolded
A law signed this summer cut funding for the NIH, the US medical research agency, by $18 billion.
[26] Why it matters
Early-stage startups need investors most, and uncertainty is keeping those investors away.
[26] Think it through
-
1
Why do big drugmakers escape?
They promised US investment and struck deals with the government, which shields them from tariffs.
[26] Promise US factoriesDeal with governmentTariffs avoided -
2
So who holds the power here?
Investors with cash: the report says tariff uncertainty keeps them on the sidelines.
[26]
How it works
Economists call it economies of scale: big firms spread a fixed cost over far more sales.
Larger drugmakers can absorb tariff costs that small biotechs cannot, the report says.
[26] Seen it before
A delivery fee hurts a small order more than a big one.
The truth
- Its count of 41 takeovers is up from 40 a year earlier, but down on the 3 quarters before.
[26]
-
Tariffs, FDA turmoil and grant cuts are hitting small biotechs hardest, an investment bank's report says.
-
19
The FDA faces years without a permanent head
What happened
-
The FDA, the US drug regulator, may go 2 years without a permanent head, former officials told Semafor.
[27] -
US Senate health committee chair Bill Cassidy predicts the job will "fall to the Senate Democrats".
[27] -
Fees paid by drug companies make up about half of the FDA's funding.
[27] -
The US Congress must renew those user fees every 5 years, and is taking them up now.
[27]
Who is involved
Possible stand-ins include Sara Brenner, acting head in early 2025, and Karim Mikhail, the FDA's vaccine regulator.
[27] - Sara Brenner
- Karim Mikhail the FDA's vaccine regulator
How it unfolded
The Trump administration pulled its nominee, Heidi Overton, at the last minute.
[27] Why it matters
If the fees lapse, the US Congress would need more than $3.5 billion of taxpayer money to fill the gap.
[27] Think it through
-
1
Why does a missing leader matter now?
FDA leaders want powers to order drug recalls and see supply-chain data.
[27] With no permanent head, it is unclear who will argue for them.[27] New powers wantedNo permanent leaderNobody to push -
2
Who objects to the fees themselves?
Bernie Sanders, who leads the Senate health committee next year, called the fees an "incredible conflict of interest".
[27] -
3
So who holds the power here?
The US Congress does: its Senate confirms any nominee, and both houses must renew the fees.
[27]
How it works
Political scientists call it regulatory capture: a watchdog paid by the industry it checks may come to lean its way.
Sanders's worry is capture: "it might be a good idea not to have the industry paying for their regulation".
[27] Seen it before
A referee paid by one team gets watched for every call that team wins.
The truth
- Nobody knows if the US Congress would find $3.5 billion should the fees end.
[27] Half the FDA's money rides on it.[27]
-
The FDA, the US drug regulator, may go 2 years without a permanent head, former officials told Semafor.
-
20
UAE bans influencers from selling medicines
What happened
-
The UAE's drug regulator banned social media influencers from promoting medical products.
[28] -
Every medical advert must have its approval before it is published.
[28] -
Adverts must state risks and side effects.
[28] They must not push people to diagnose or prescribe for themselves.[28] -
Prescription-only medicines can now be advertised, but only under the regulator's rules.
[28]
Who is involved
The regulator, the Emirates Drug Establishment, set out the rules at a meeting in Dubai.
[28] - Emirates Drug Establishment the UAE's drug regulator
How it unfolded
In August the Dubai Health Authority warned clinics about misleading medical claims on social media.
[28] - August Dubai warns clinics
- This week influencer ban
Why it matters
Dubai's cosmetic clinics, which find patients on Instagram and TikTok, are expected to feel it most.
[28] Think it through
-
1
Why aim at influencers?
Influencers have pushed cosmetic treatments with before-and-after photos and claims of guaranteed results.
[28] Before-and-after photosPromised resultsPatients book -
2
So who enforces it?
The regulator will work with other authorities to remove adverts that break the rules.
[28]
How it works
Health regulators call it pre-approval: an advert is checked before anyone sees it, not after harm is done.
Under this pre-approval rule, every UAE medical advert must clear the Emirates Drug Establishment before it runs.
[28] Seen it before
A school checks a poster before it goes up, not after it is on the wall.
The truth
- People at the meeting asked for a simpler approval process, since every advert must now pass it first.
[28]
-
The UAE's drug regulator banned social media influencers from promoting medical products.
More Biotech editions
Across the beats